Villalona-Calero, M. A., Patnaik, A., Maki, R. G., O’Neil, B., Abbruzzese, J. L., Dagogo-Jack, I., … Ahnert, J. R. (2022). Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Villalona-Calero, Miguel Angel, Amita Patnaik, Robert G. Maki, Bert O’Neil, James L. Abbruzzese, Ibiayi Dagogo-Jack, Siddhartha Devarakonda, et al. “Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Villalona-Calero MA, Patnaik A, Maki RG, O’Neil B, Abbruzzese JL, Dagogo-Jack I, et al. Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Villalona-Calero, Miguel Angel, et al. “Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Villalona-Calero MA, Patnaik A, Maki RG, O’Neil B, Abbruzzese JL, Dagogo-Jack I, Devarakonda S, Wahlroos S, Lin C-C, Fujiwara Y, Terbuch A, Postel-Vinay S, Goebeler M-E, Addeo A, Prenen H, Arkenau T, Sacher AG, Liu C, Kormany W, Ahnert JR. Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2022.